SRRK (Scholar Rock Corp) Net earnings per share (EPS TTM)

Scholar Rock Corp (SRRK) - corporate logo

Strategic alliances with global centers are accelerating trials for muscle atrophy treatments. The rolling year net income per share dynamics illustrate the current trend, where -3.40 serves as the base parameter value. The prospects for Scholar Rock (SRRK) rely on FDA approval and the success of the drug apitegromab. Innovative methods for restoring muscle function open new therapeutic opportunities for neurodegenerative pathologies.

Scholar Rock Corp - SRRK Earnings per share for the last twelve months (period 02/11/2024 - 11/18/2026)

SRRK (Scholar Rock, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental company valuation:SRRK Scholar Rock Corp
Flagship merchandise of Scholar Rock Holding Corporation

For Scholar Rock (SRRK), which is currently in a phase of costly clinical trials, the annual EPS growth rate over the last 12 months reflects the impact of rising operating expenses on net income. This indicator measures earnings per share dynamics, allowing investors to assess cost management efficiency and the extent to which business scaling pressures the bottom line prior to the commercialization stage.

Direct competitors